降糖、减肥药等助推下 中国西药制剂出口金额占比创历史新高

Core Insights - China is transitioning its pharmaceutical exports from raw materials to higher value-added finished drug formulations, with significant growth projected for 2025 [1][3]. Group 1: Export Growth Projections - By 2025, China's export value of Western medicine formulations is expected to reach $8.841 billion, representing a year-on-year increase of 27.29% [1]. - The share of formulations in the total Western medicine exports will reach a historical high of 15.85% [1]. - Formulations are projected to account for 7.94% of the overall pharmaceutical exports, indicating a clear upward trend [1]. Group 2: Performance Metrics - The overall performance of Western medicine formulations in 2025 is characterized by simultaneous increases in both volume and price, with export volume rising by 17.71% and export price increasing by 8.01% year-on-year [1]. - Exports to the EU (excluding the UK) represent the largest market share, with a year-on-year growth of 70.4%, an increase of approximately 10 percentage points compared to 2024 [1]. Group 3: Key Product Categories - Hormonal drugs are the primary driver of the significant growth in formulation exports, with an export value of $3.153 billion, marking a 106% year-on-year increase [2]. - The export value of insulin analogs and GLP-1 peptide drugs reached $2.977 billion, showing a remarkable growth of 110.90% [2]. Group 4: Market Dynamics - The surge in demand for insulin analogs and GLP-1 drugs is attributed to the rising incidence of metabolic diseases such as diabetes and obesity [3]. - Multinational companies are shifting their strategies from focusing solely on finished product imports to enhancing local production capabilities, positioning China as a key global supply chain hub [3]. - Domestic companies are achieving technological breakthroughs and expanding production capacity in the insulin and GLP-1 sectors, actively participating in international markets and seeking regulatory approvals from agencies like the FDA and EMA [3].